(3-Chlorophenyl)boronic acid → 3'-Chloro-N-[5-(cis-3,5-dimethyl-1-piperazinyl)-2-(methyloxy)phenyl]-4-biphenylsulfonamide

HRID 130446

Reaktionsgleichung

Reaktionsgleichung von HRID 130446
Br[C:2]1[CH:7]=[CH:6][C:5]([S:8]([NH:11][C:12]2[CH:17]=[C:16]([N:18]3[CH2:23][C@H:22]([CH3:24])[NH:21][C@H:20]([CH3:25])[CH2:19]3)[CH:15]=[CH:14][C:13]=2[O:26][CH3:27])(=[O:10])=[O:9])=[CH:4][CH:3]=1.[Cl:28][C:29]1[CH:30]=[C:31](B(O)O)[CH:32]=[CH:33][CH:34]=1.CC(C)([O-])C.[K+]>COCCOC.O.C1C=CC([P]([Pd]([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)([P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)[P](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC=1>[Cl:28][C:29]1[CH:34]=[C:33]([C:2]2[CH:3]=[CH:4][C:5]([S:8]([NH:11][C:12]3[CH:17]=[C:16]([N:18]4[CH2:19][C@H:20]([CH3:25])[NH:21][C@H:22]([CH3:24])[CH2:23]4)[CH:15]=[CH:14][C:13]=3[O:26][CH3:27])(=[O:10])=[O:9])=[CH:6][CH:7]=2)[CH:32]=[CH:31][CH:30]=1

Komponenten

7

Edukt 3

HCID 2734323(3-Chlorophenyl)boronic acidHCID 23665647Potassium tert-butoxideHCID 444527764-Bromo-N-[5-(cis-3,5-dimethyl-1-piperazinyl)-2-(methyloxy)phenyl]benzenesulfonamide

Produkt 1

HCID 590070813'-Chloro-N-[5-(cis-3,5-dimethyl-1-piperazinyl)-2-(methyloxy)phenyl]-4-biphenylsulfonamide

Reagenzien, Katalysatoren, Lösungsmittel 3

HCID 178418397HCID 178418397, VerbindungKatalysatorHCID 962WaterLösungsmittelHCID 80711,2-DimethoxyethaneLösungsmittel

Reaktionsbedingungen

Temperatur
100 °C

Versuchsvorschrift

To a mixture of 4-bromo-N-[5-(cis-3,5-dimethyl-1-piperazinyl)-2-(methyloxy)phenyl]benzenesulfonamide (E106) (75 mg, 0.17 mmol) and (3-chlorophenyl)boronic acid (56 mg, 0.36 mmol) in DME (3 ml) was added potassium tert-butoxide (180 mg, 1.60 mmol) and tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.01 mmol) in water (1 ml) and the resulting mixture stirred in a microwave (set at high absorbance) at 100° C. for 30 minutes. The resulting mixture was then evaporated in vacuo and purified using an SCX cartridge eluting with methanol followed by ammonia (2M in methanol). The appropriate fractions were combined and evaporated in vacuo and the residue purified further by mass directed autoprep HPLC to afford the title compound (E111). MS (ES+) m/e 486/488 [M+H]+.

Aufarbeitung

  1. customThe resulting mixture was then evaporated in vacuo
  2. custompurified
  3. washeluting with methanol
  4. customevaporated in vacuo
  5. customthe residue purified further by mass

Quellen und Nachweise

ORD-Eintrag
ord-66994927e0a249ea89366cc7dc7e81b2
Quelldatensatz
uspto-grants-2008_06
Patentnummer
US07381728B2

Verknüpfte Notizen

Wird geladen…